NASDAQ:STIM Neuronetics (STIM) Stock Forecast, Price & News $1.28 -0.07 (-4.81%) (As of 02:33 PM ET) Add Compare Share Share Today's Range$1.26▼$1.3650-Day Range$1.29▼$2.0252-Week Range$1.25▼$6.95Volume86,897 shsAverage Volume186,519 shsMarket Capitalization$37.10 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Neuronetics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside639.3% Upside$9.50 Price TargetShort InterestHealthy1.49% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$32,409 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.13) to ($0.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.50 out of 5 starsMedical Sector171st out of 969 stocksSurgical & Medical Instruments Industry26th out of 100 stocks 3.5 Analyst's Opinion Consensus RatingNeuronetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Neuronetics has a forecasted upside of 639.3% from its current price of $1.29.Amount of Analyst CoverageNeuronetics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.49% of the outstanding shares of Neuronetics have been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuronetics has recently decreased by 6.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for STIM. Previous Next 2.0 News and Social Media Coverage News SentimentNeuronetics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Neuronetics this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,409.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions62.23% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($1.13) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neuronetics (NASDAQ:STIM) StockNeuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Read More STIM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STIM Stock News HeadlinesSeptember 21, 2023 | benzinga.comBoard Member of Neuronetics Purchased $51K In StockSeptember 12, 2023 | finance.yahoo.comIn Recognition of Suicide Prevention Month, NeuroStar Voices Portal Amplifies Stories of Real People Beating DepressionOctober 2, 2023 | Stansberry Research (Ad)U.S. "Shadow Banks" About to Blow up again?Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.September 6, 2023 | msn.comNeuronetics: Large Losses May Be Repelling InvestorsAugust 24, 2023 | 247wallst.comCannell Capital Now Owns 8.45% of NeuroneticsAugust 19, 2023 | finance.yahoo.comCannell Capital LLC Reduces Stake in Neuronetics IncAugust 14, 2023 | finance.yahoo.comNeuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® PlatformAugust 11, 2023 | finance.yahoo.comNeuronetics (STIM) Upgraded to Buy: What Does It Mean for the Stock?October 2, 2023 | Goldco (Ad)Warren Buffett: Stark Warning On InflationAccording to a recent letter to Berkshire Hathaway shareholders, “Billionaire Investment Guru Warren Buffett issues stark inflation warning”. The new numbers have shown a comeback for inflation, surging to its highest levels in six months, and it’s now looking like there’s little chance our policy makers can put this cat back in the bag. That’s why it’s critical you heed Warren’s Buffett’s advice and “brace yourself”, before it’s too late. Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late! August 9, 2023 | markets.businessinsider.comNeuronetics (STIM) Receives a Buy from JMP SecuritiesAugust 8, 2023 | finance.yahoo.comNeuronetics Reports Record Second Quarter 2023 Financial and Operating ResultsJuly 25, 2023 | finance.yahoo.comNeuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference CallJuly 22, 2023 | ca.finance.yahoo.comSTIM - Neuronetics, Inc.July 19, 2023 | finance.yahoo.comNeuronetics Announces Expanded TMS Therapy Access Through Aetna® Health PlansJuly 17, 2023 | finance.yahoo.comNeuroStar Achieves Milestone Regulatory Clearance in South KoreaJuly 11, 2023 | finance.yahoo.comNeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB PlayerJuly 5, 2023 | morningstar.comNeuronetics Inc STIM Stock QuoteJune 12, 2023 | finance.yahoo.comNeuronetics Receives 510(k) Clearance for OCD MT Cap for NeuroStar Advanced TherapyJune 8, 2023 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) Could Be Riskier Than It LooksMay 26, 2023 | finance.yahoo.comNeuronetics Announces Increased TMS Access Through BlueCross BlueShield Of MichiganMay 24, 2023 | finance.yahoo.comNeuronetics to Present at the William Blair 43rd Annual Growth Stock ConferenceMay 23, 2023 | technews.tmcnet.comNew Depression Barometer Survey Shows Patients Are Stopping Treatment Due to DissatisfactionMay 15, 2023 | finance.yahoo.comNeuronetics Wins 2023 Bell Seal for Workplace Mental HealthMay 12, 2023 | msn.comJMP Securities Reiterates Neuronetics (STIM) Market Outperform RecommendationMay 10, 2023 | marketwatch.comTMS (Transcranial Magnetic Stimulation) Coil Market Forecast 2023-2030May 9, 2023 | finance.yahoo.comNeuronetics Reports Record First Quarter 2023 Financial and Operating ResultsMay 8, 2023 | finance.yahoo.comNeuronetics Receives MDSAP Certification and CE Mark Certification under New MDRSee More Headlines Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Email Address STIM Company Calendar Last Earnings8/08/2023Today10/02/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STIM CUSIPN/A CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees209Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.50 High Stock Price Forecast$12.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+603.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,160,000.00 Net Margins-46.16% Pretax Margin-46.16% Return on Equity-58.58% Return on Assets-28.46% Debt Debt-to-Equity Ratio0.81 Current Ratio5.17 Quick Ratio4.58 Sales & Book Value Annual Sales$65.21 million Price / Sales0.60 Cash FlowN/A Price / Cash FlowN/A Book Value$2.10 per share Price / Book0.64Miscellaneous Outstanding Shares28,870,000Free Float27,372,000Market Cap$38.97 million OptionableNot Optionable Beta1.83 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Keith J. Sullivan (Age 65)Pres, CEO & Director Comp: $1.53MMr. Stephen J. Furlong M.S. (Age 59)Exec. VP, CFO & Treasurer Comp: $787.87kMr. W. Andrew Macan (Age 50)Exec. VP, GC, Chief Compliance Officer & Corp. Sec. Comp: $646.55kMr. Rusty PageSr. VP of Operations & QualityMs. Lisa Metzner-RosasSr. VP & Chief Marketing OfficerMs. Kara ThorntonSr. VP of HRMs. Sara GrubbsSr. VP & Chief Revenue OfficerMr. Rick GrubbsSr. VP of National AccountsMr. Todd CushmanSr. VP of Bus. Devel.Mr. Cory S. AndersonSr. VP of R&D and ClinicalMore ExecutivesKey CompetitorsRetractable TechnologiesNYSE:RVPLENSARNASDAQ:LNSRPAVmedNASDAQ:PAVMCo-DiagnosticsNASDAQ:CODXAkiliNASDAQ:AKLIView All CompetitorsInsiders & InstitutionsPortside Wealth Group LLCBought 16,815 shares on 9/1/2023Ownership: 0.058%Kent Lake Capital LLCSold 138,226 shares on 8/15/2023Ownership: 2.447%XTX Topco LtdSold 33,434 shares on 8/15/2023Ownership: 0.389%Goldman Sachs Group Inc.Sold 10,746 shares on 8/15/2023Ownership: 0.104%Citadel Advisors LLCBought 2,900 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions STIM Stock - Frequently Asked Questions Should I buy or sell Neuronetics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STIM shares. View STIM analyst ratings or view top-rated stocks. What is Neuronetics' stock price forecast for 2023? 2 brokers have issued 1 year price objectives for Neuronetics' shares. Their STIM share price forecasts range from $7.00 to $12.00. On average, they expect the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 603.7% from the stock's current price. View analysts price targets for STIM or view top-rated stocks among Wall Street analysts. How have STIM shares performed in 2023? Neuronetics' stock was trading at $6.87 at the beginning of the year. Since then, STIM stock has decreased by 80.3% and is now trading at $1.35. View the best growth stocks for 2023 here. When is Neuronetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our STIM earnings forecast. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) posted its earnings results on Tuesday, August, 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.17. The firm had revenue of $17.61 million for the quarter, compared to analyst estimates of $17.44 million. Neuronetics had a negative trailing twelve-month return on equity of 58.58% and a negative net margin of 46.16%. What guidance has Neuronetics issued on next quarter's earnings? Neuronetics issued an update on its third quarter 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $17.00 million-$18.00 million, compared to the consensus revenue estimate of $17.80 million. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST). When did Neuronetics IPO? (STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. What is Neuronetics' stock symbol? Neuronetics trades on the NASDAQ under the ticker symbol "STIM." How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neuronetics' stock price today? One share of STIM stock can currently be purchased for approximately $1.35. How much money does Neuronetics make? Neuronetics (NASDAQ:STIM) has a market capitalization of $38.97 million and generates $65.21 million in revenue each year. The company earns $-37,160,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. How many employees does Neuronetics have? The company employs 209 workers across the globe. How can I contact Neuronetics? Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The official website for the company is www.neurostar.com. The company can be reached via phone at (610) 640-4202, via email at ir@neuronetics.com, or via fax at 610-640-4206. This page (NASDAQ:STIM) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.